A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Phase of Trial: Phase I
Latest Information Update: 13 Sep 2017
At a glance
- Drugs AZD 9150 (Primary) ; Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions
- Sponsors MedImmune
- 07 Sep 2017 Planned number of patients changed from 180 to 207.
- 07 Sep 2017 Planned End Date changed from 5 Jul 2021 to 30 Nov 2022.
- 07 Sep 2017 Planned primary completion date changed from 5 Jul 2021 to 30 Nov 2022.